China Clinical Data Crackdown Sees Device-Makers Withdraw 101 Applications
China FDA is now relentlessly clamping down on clinical data irregularities in the medtech industry, causing 51 manufacturers, including well-known multinational companies such as Boston Scientific and Olympus, to withdraw more than a hundred new device approvals filed with the agency.
You may also be interested in...
The China Food and Drug Administration wants to expand the scope of products subject to recall and increase the penalties for wrongdoers.
China's Food and Drug Administration invited feedback on a new batch of medical devices that it intends to exempt from having to undergo local clinical trials. The agency's proposal, if adopted, would make it much easier and less costly for companies that want to place these devices on the Chinese market.
China releases technical requirements for foreign drug makers to register their chemical drugs in the country, and issues patent linkage details, which a legal expert says needs to be closely examined.